Methods: Participants were recruited from two opioid substitution treatment clinics and one medically supervised injecting centre between November 2015 and February 2016. The four recruitment categories were: a) high FibroScan ® score (≥9.5 kPa)/ attended LiveRLife follow-up; b) high score/did not attend follow-up; c) low score (≤9.4 kPa)/attended follow-up; and d) low score/did not attend follow-up. Participants were not reminded of their category during recruitment. Inclusion criteria were: participation in the LiveRLife campaign, received a FibroScan ® score, and informed written consent. Interviews were audio-taped and transcribed verbatim. Data was analysed using thematic analysis.
Results:
Of 33 semi-structured interviews [category a (12 participants); category b (2); category c (11); category d (8); 21% female], reasons for wanting to receive a FibroScan ® were varied. Most participants interpreted their level of liver disease correctly based on their recalled FibroScan ® score. Persons with higher scores frequently recalled feeling shocked by their score (e.g. 'wake-up call') whereas participants with lower scores were typically pleasantly surprised (e.g. incentive to keep liver healthy). Some positive health changes were stated with several relating their score to hepatitis C treatment. Additionally, some confusion regarding causes of increased liver disease persisted despite this information being provided in the campaign. Further analyses will explore health-seeking behaviours (or lack thereof) by category.
